Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation

Journal of Hepatology

Volumn 54, Issue 4, 2011, Pages 695-704

  Riaz, Ahsun ^a   Memon, Khairuddin ^a   Miller, Frank H ^a   Nikolaidis, Paul ^a   Kulik, Laura M ^a   Lewandowski, Robert J ^a   Ryu, Robert K ^a   Sato, Kent T ^a   Gates, Vanessa L ^a   Mulcahy, Mary F ^a   Baker, Talia ^a   Wang, Ed ^a   Gupta, Ramona ^a   Nayar, Ritu ^a   Benson III, Al B ^a   Abecassis, Michael ^a   Omary, Reed ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Imaging; Locoregional therapies; Pathologic correlation

Indexed keywords

ANTINEOPLASTIC AGENT; YTTRIUM 90;

AGED; ARTICLE; AUTOPSY; CANCER STAGING; CHEMOEMBOLIZATION; ETHNICITY; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER NECROSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

AGED; CARCINOMA, HEPATOCELLULAR; EUROPE; FEMALE; HUMANS; INTERNATIONAL AGENCIES; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; ROC CURVE; WORLD HEALTH ORGANIZATION;

EID: 79952696628     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.10.004     Document Type: Article

References (41)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36 (5 Suppl. 1):S74-S83. (Pubitemid 35253466)
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334 (11):693-699. (Pubitemid 26079803)
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359 (4):378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10 (1):25-34.
5. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138 (1):52-64.
6. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver transpl 2004;10 (3):449-455. (Pubitemid 38380323)
7. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9 (8):1920-1928.
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359 (9319):1734-1739. (Pubitemid 34607087)
9. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35 (5):1164-1171. (Pubitemid 34454013)
10. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2010. doi:10.1053/j.gastro.2010.10.049.
11. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25 (13):1753-1759. (Pubitemid 46797957)
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45 (2):228-247.
13. WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication, Geneva, Switzerland, WHO; 1979. No.48.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92 (3):205-216.
15. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (Baltimore, Md) 2009;49 (4):1185-1193.
16. Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 2010;33 (6):1143-1152.
17. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35 (3):421-430. (Pubitemid 32844200)
18. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115 (3):616-623.
19. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008;31 (2):269-280.
20. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33 (1):41-52.
21. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33 (3):541-551.
22. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24 (20):3245-3251. (Pubitemid 46622065)
23. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42 (5):1208-1236. (Pubitemid 43112690)
24. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10 (2 Suppl. 1):S115-S120. (Pubitemid 38240111)
25. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134 (6):1752-1763. (Pubitemid 351615415)
26. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127 (5 Suppl. 1):S179-188.
27. TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada; 2004.
28. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13 (9 Pt. 2):S223-229.
29. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006;17 (8):1251-1278. (Pubitemid 44259009)
30. Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010;303 (11):1062-1069.
31. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33 (10):533-537. (Pubitemid 43115248)
32. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33 (1):159-174. (Pubitemid 8054849)
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
34. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39(4):561-577. (Pubitemid 23118304)
35. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143 (1):29-36. (Pubitemid 12142173)
36. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148 (3):839-843. (Pubitemid 13033817)
37. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100 (10):698-711.
38. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40 (6):1352-1360. (Pubitemid 39657009)
39. Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008;19 (8):1180-1186.
40. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18 (1 Pt. 1):49-56. (Pubitemid 46616678)
41. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular